Cosentyx Gains FDA Approval for Scalp Psoriasis
The FDA has approved a label update for secukinumab (Cosentyx) for the treatment of moderate-to-severe scalp psoriasis, according to a Novartis press release. Scalp psoriasis affects approximately half of patients with psoriasis and is notoriously difficult to treat due to the presence of hair and other related factors.
The label will be updated in the United States immediately, according to the release.
“Scalp psoriasis is on a very sensitive, and a very visible area of the body. For patients this could translate into physical pain, frustration and social isolation,” said Kristian Reich, MD, PhD, Georg-August-University Göttingen and Dermatologikum Hamburg, Germany. “Patients and doctors are in need of effective treatment options in this and other difficult-to-treat forms of psoriasis."
thumbnail courtesy of specialtypharmacytimes.com
Check out other psoriasis news here.
Additional reading: The Top 3 Psoriasis Shampoos – The Best Over the Counter Psoriasis Shampoo
Cosentyx Gains FDA Approval for Scalp Psoriasis was originally published to: Psoriasis Zap Blog
Comments
Post a Comment